International Scholarly Research Notices

Research Article

Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda

Table 5

Risk factors for borderline hyperglycemia.


Characteristics	Odds ratio	95% CI	value	Adjusted odds ratio	95% CI	value

Male gender	0.76	0.44–1.33	0.336	0.93	0.41–2.12	0.855
Stavudine-based ART regimen	0.58	0.33–1.01	0.055	0.50	0.27–0.93	0.028
Age	1.32*	1.14–1.54	0.001	1.31	1.11–1.56	0.002
ART duration	1.09	0.82–1.46	0.550
Initial CD4 counts per 50 cells/μL increase	0.94	0.80–1.11	0.463
ART start body weight	1.00	0.97–1.03	0.95
Peak body weight 65 kgs	1.00	0.92–1.09	0.957
Enrolment BMI 24	1.00	1.00–1.02	0.213
Systolic blood pressure 150 mm/Hg	1.02	1.00– 1.03	0.05	1.01	0.90–1.03	0.146
Enrolment CD4 count 200 cells/μL	1.06	0.55–2.05	0.86
Abnormal waist to hip ratio⁺	1.97	1.01–3.84	0.046	1.73	0.67–4.46	0.255
Family history of hypertension	0.99	0.57–1.73	0.972
Family history of diabetes mellitus	1.71	0.91–3.22	0.095	2.18	1.10–4.34	0.026
Lipodystrophy	0.98	0.56–1.89	0.946
WHO stage III and IV	1.00	0.54–1.85	0.991

CI: confidence interval; ART: antiretroviral treatment; BMI: body mass index; WHO: World Health Organization.
⁺WHR defined abnormal if 0.94 for males and 0.8 for females.
*Denote that age as a variable was supposed to be interpreted as a 5-year increase as interpreted in the text.